{"protocolSection": {"identificationModule": {"nctId": "NCT06486441", "orgStudyIdInfo": {"id": "GS-US-682-6769"}, "secondaryIdInfos": [{"id": "2024-511957-23", "type": "OTHER", "domain": "European Medicines Agency"}, {"id": "GOG-3104", "type": "OTHER", "domain": "The GOG Foundation"}, {"id": "ENGOT-en26", "type": "OTHER", "domain": "European Network for Gynaecological Oncological Trial Groups"}], "organization": {"fullName": "Gilead Sciences", "class": "INDUSTRY"}, "briefTitle": "Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)", "officialTitle": "A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy", "acronym": "ASCENT-GYN-01"}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Gilead Sciences", "class": "INDUSTRY"}, "collaborators": [{"name": "GOG Foundation", "class": "NETWORK"}, {"name": "European Network of Gynaecological Oncological Trial Groups (ENGOT)", "class": "OTHER"}]}, "descriptionModule": {"briefSummary": "The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC).\n\nThe primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS)."}, "conditionsModule": {"conditions": ["Endometrial Cancer"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 520, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sacituzumab Govitecan (SG)", "type": "EXPERIMENTAL", "description": "Participants will receive SG at a dose of 10 mg/kg on Days 1 and 8 of a 21-day cycle.", "interventionNames": ["Drug: Sacituzumab govitecan-hziy"]}, {"label": "Treatment of Physician's Choice (TPC)", "type": "ACTIVE_COMPARATOR", "description": "Participants will receive one of the following TPC, regimens determined prior to randomization.\n\n* Doxorubicin 60 mg/m\\^2 IV on Day 1 of a 21-day cycle\n* Paclitaxel 80 mg/m\\^2 IV on Days 1, 8, and 15 of a 28-day cycle", "interventionNames": ["Drug: Doxorubicin", "Drug: Paclitaxel"]}], "interventions": [{"type": "DRUG", "name": "Sacituzumab govitecan-hziy", "description": "Administered intravenously", "armGroupLabels": ["Sacituzumab Govitecan (SG)"], "otherNames": ["Trodelvy\u2122", "GS-0132"]}, {"type": "DRUG", "name": "Doxorubicin", "description": "Administered intravenously", "armGroupLabels": ["Treatment of Physician's Choice (TPC)"], "otherNames": ["Adriamycin"]}, {"type": "DRUG", "name": "Paclitaxel", "description": "Administered intravenously", "armGroupLabels": ["Treatment of Physician's Choice (TPC)"], "otherNames": ["Taxol"]}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion Criteria:\n\n* Documented evidence of recurrent/persistent endometrial cancer (endometrial carcinoma or carcinosarcoma).\n* Up to 3 prior lines of systemic therapy for endometrial cancer, including systemic platinum-based chemotherapy and anti-PD-1/PD-L1 therapy, either in combination or separately.\n* Eligible for treatment with either doxorubicin or paclitaxel as determined by the investigator.\n* Radiologically evaluable disease (either measurable or nonmeasurable) by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1.\n* Eastern Cooperative Oncology Group performance status score of 0 or 1.\n* Adequate organ function\n\nKey Exclusion Criteria:\n\n* Uterine leiomyosarcoma and endometrial stromal sarcomas are excluded.\n* Participants who are candidates for curative-intent therapy at the time of study enrollment.\n* Participants eligible for rechallenge with platinum-based chemotherapy as determined by the investigator.\n* Received any prior treatment with a Trop-2-directed antibody-drug conjugate (ADC).\n* Have an active second malignancy.\n* Have an active serious infection requiring systemic antimicrobial therapy.\n* Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal perforation within 6 months prior to randomization.\n* Have a positive serum pregnancy test or are breastfeeding for participants who are assigned female at birth.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Gilead Clinical Study Information Center", "role": "CONTACT", "phone": "1-833-445-3230 (GILEAD-0)", "email": "GileadClinicalTrials@gilead.com"}], "overallOfficials": [{"name": "Gilead Study Director", "affiliation": "Gilead Sciences", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Gilead Clinical Trials Website", "url": "https://www.gileadclinicaltrials.com/study?nctid=NCT06486441"}]}}, "hasResults": false}